Robert “Bob” Tepper is a distinguished scientist with over 25 years of experience building and operating leading R&D operations. Bob co-founded Third Rock Ventures in 2007 and focuses on the formation, development and scientific strategy of TRV portfolio companies as well as actively identifying and evaluating new investments. Prior to joining Third Rock Ventures, Bob was President of R&D at Millennium Pharmaceuticals and was vital in its expansion from a drug discovery company to a fully integrated biopharmaceutical company. Prior to Millennium, Bob co-founded Cell Genesys/Abgenix. Bob holds an AB in Biochemistry from Princeton University and his MD degree from Harvard Medical School. Bob serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions including the Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Tufts Medical School. Bob is a Board Member of Cerulean Pharmaceuticals and is on the Board of Overseers at Tufts University. He also serves on the Council of the National Center for the Advancement of Translational Sciences (NCATS) at the National Institutes of Health (NIH).